BV-CHP Real-life and Biological Evidences in Patients With sALCL

Key facts

Sponsor

Fondazione Italiana Linfomi - ETS

Principal Investigator

Carla Minoia, MD

Bari - I.R.C.C.S. Istituto Tumori Giovanni Paolo II - U.O.C. Ematologia

Enrollment

100 enrolled

Eligibility

18 years · All sexes

Timeline

2026 – 2028

Study locations (19)

• A.O.R.N. S. Giuseppe Moscati - S.C. Ematologia e Trapianto emopoietico, Avellino, Italy
• I.R.C.C.S. Centro di Riferimento Oncologico - S.O.C. Oncologia medica e dei tumori immuno-correlati, Aviano, Italy
• I.R.C.C.S. Istituto Tumori Giovanni Paolo II - U.O.C. Ematologia, Bari, Italy
• A.S.S.T Papa Giovanni XXIII - S.C. Ematologia, Bergamo, Italy
• I.R.C.C.S. A.O.U. di Bologna Policlinico S. Orsola - U.O. Ematologia, Bologna, Italy
• I.R.C.C.S. Istituto di Candiolo - FPO, Candiolo, Italy
• A.S.S.T. Ovest Milanese Ospedale di Legnano - U.O.C. di Ematologia, Legnano, Italy
• A.S.S.T. Grande Ospedale Metropolitano Niguarda - S.C. Ematologia, Milan, Italy
• I.R.C.C.S. Istituto Europeo di Oncologia - U.O. Oncoematologia, Milan, Italy
• I.R.C.C.S. Ospedale San Raffaele - U.O. Ematologia e Trapianto di Midollo Osseo, Milan, Italy
• A.S.L. di Pescara P.O. Santo Spirito - U.O.C. Ematologia, Pescara, Italy
• A.U.S.L. di Piacenza Osp. Guglielmo da Saliceto - U.O.C. Ematologia e Centro Trapianti, Piacenza, Italy
• I.R.C.C.S. Fondazione Policlinico Universitario Gemelli - U.O.S.D. Malattie linfoproliferative extramidollari, Roma, Italy
• IRCCS Humanitas Research Hospital - U.O. Ematologia, Rozzano, Italy
• A.O. Ordine Mauriziano - S.C.D.U. Ematologia, Torino, Italy
• +4 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for ALK-negative anaplastic large cell lymphoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT07300514
  Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma
  Fudan University
• RECRUITINGPHASE2NCT07356245
  Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
  Jonathan Brammer
• RECRUITINGPHASE1NCT06176690
  Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
  Baylor College of Medicine
• RECRUITINGPHASE1NCT07001384
  A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)
  Memorial Sloan Kettering Cancer Center
• ACTIVE NOT RECRUITINGPHASE2NCT07013565
  Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
  New York Medical College
• RECRUITINGPHASE2NCT05996185
  Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
  Yale University
• RECRUITINGPHASE1NCT06508463
  Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
  Mayo Clinic
• RECRUITINGPHASE1, PHASE2NCT04925609
  Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
  Princess Maxima Center for Pediatric Oncology

See all trials for ALK-negative anaplastic large cell lymphoma →